摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazoline-7-carbonitrile

中文名称
——
中文别名
——
英文名称
2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazoline-7-carbonitrile
英文别名
——
2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazoline-7-carbonitrile化学式
CAS
——
化学式
C20H16N6
mdl
——
分子量
340.4
InChiKey
CJCOMWIWICGMIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    90.3
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • Pyrazole compounds useful as protein kinase inhibitors
    申请人:Bebbington David
    公开号:US20070270444A1
    公开(公告)日:2007-11-22
    This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    该发明描述了式IV的新型吡唑化合物: 其中环D为从芳基,杂芳基,杂环基或碳环基中选择的5-7成员单环或8-10成员双环;Rx和Ry独立地选择自T-R3,或者与它们之间的原子结合形成融合的、不饱和的或部分不饱和的、具有1-3个环杂原子的5-8成员环;而R2,R2',T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂,特别是作为aurora-2和GSK-3的抑制剂,用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
  • PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Bebbington David
    公开号:US20100256170A1
    公开(公告)日:2010-10-07
    This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    本发明描述了式IV的新型吡唑化合物:其中环D为5-7成员单环或8-10成员双环,选自芳基,杂芳基,杂环基或碳环基;Rx和Ry分别选自T-R3,或与其之间的原子结合形成融合的、不饱和或部分不饱和的5-8成员环,其中有1-3个选自氧、硫或氮的环杂原子;R2、R2'、T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂,特别是aurora-2和GSK-3的抑制剂,用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
  • US7390815B2
    申请人:——
    公开号:US7390815B2
    公开(公告)日:2008-06-24
  • US7473691B2
    申请人:——
    公开号:US7473691B2
    公开(公告)日:2009-01-06
  • US7691853B2
    申请人:——
    公开号:US7691853B2
    公开(公告)日:2010-04-06
查看更多